Investigational Drug Information for Pardoprunox
✉ Email this page to a colleague
What is the development status for investigational drug Pardoprunox?
Pardoprunox is an investigational drug.
There have been 6 clinical trials for Pardoprunox.
The most recent clinical trial was a Phase 3 trial, which was initiated on August 1st 2007.
The most common disease conditions in clinical trials are Parkinson Disease, Dyskinesias, and [disabled in preview]. The leading clinical trial sponsors are Solvay Pharmaceuticals, Abbott Products, and [disabled in preview].
Summary for Pardoprunox
| US Patents | 0 |
| International Patents | 0 |
| US Patent Applications | 73 |
| WIPO Patent Applications | 59 |
| Japanese Patent Applications | 14 |
| Clinical Trial Progress | Phase 3 (2007-08-01) |
| Vendors | 44 |
Recent Clinical Trials for Pardoprunox
| Title | Sponsor | Phase |
|---|---|---|
| A Pilot Study to Assess Efficacy and Safety of Pardoprunox as Adjunct Therapy to L-dopa in the Treatment of Patients With Parkinson's Disease Experiencing Motor Fluctuations and Dyskinesia. | Abbott Products | Phase 2 |
| An Open Label SLV308 Safety Extension to Study S308.3.003 in Early PD Patients | Solvay Pharmaceuticals | Phase 3 |
| An Open Label SLV308 Safety Extension to Study S308.3.002 in Patients With Parkinson's Disease Experiencing Motor Fluctuations. | Solvay Pharmaceuticals | Phase 3 |
Clinical Trial Summary for Pardoprunox
Top disease conditions for Pardoprunox
Top clinical trial sponsors for Pardoprunox
US Patents for Pardoprunox
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
